{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:25:53Z","timestamp":1788326753639,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10787-026-02149-x","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:20:56Z","timestamp":1772551256000},"page":"3783-3795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-9305","authenticated-orcid":false,"given":"Martin","family":"Cevallos-Cueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5582-7535","authenticated-orcid":false,"given":"Chinenye","family":"Onejeme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7918-0107","authenticated-orcid":false,"given":"Laura","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9624-9561","authenticated-orcid":false,"given":"Lorena Oliveira","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-0580","authenticated-orcid":false,"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2149_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13555-016-0131-8","volume":"6","author":"M Abrouk","year":"2016","unstructured":"Abrouk M, Nakamura M, Zhu TH et al (2016) The patient\u2019s guide to psoriasis treatment. Part 3: biologic injectables. Dermatol Ther 6:325\u2013331. https:\/\/doi.org\/10.1007\/s13555-016-0131-8","journal-title":"Dermatol Ther"},{"key":"2149_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/aas.14386","volume":"68","author":"Z Al Duhailib","year":"2024","unstructured":"Al Duhailib Z, Granholm A, Alhazzani W et al (2024) Grade pearls and pitfalls\u2014Part 1: systematic reviews and meta-analyses. Acta Anaesthesiol Scand 68:584\u2013592. https:\/\/doi.org\/10.1111\/aas.14386","journal-title":"Acta Anaesthesiol Scand"},{"key":"2149_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 88:29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A et al (2020) Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol 156:258. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"2149_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A et al (2017) The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 77:667\u2013674. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.033","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK et al (2024) An oral interleukin-23\u2013receptor antagonist peptide for plaque psoriasis. N Engl J Med 390:510\u2013521. https:\/\/doi.org\/10.1056\/NEJMoa2308713","journal-title":"N Engl J Med"},{"key":"2149_CR7","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","volume":"393","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Soung J, Hebert AA et al (2025) Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med 393:1784\u20131795. https:\/\/doi.org\/10.1056\/NEJMoa2504187","journal-title":"N Engl J Med"},{"key":"2149_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405\u2013417. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201","volume":"13","author":"J Bu","year":"2022","unstructured":"Bu J, Ding R, Zhou L et al (2022) Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 13:880201. https:\/\/doi.org\/10.3389\/fimmu.2022.880201","journal-title":"Front Immunol"},{"key":"2149_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A et al (2018) Psoriasis in special localizations. Rheumatology 56:392\u2013398. https:\/\/doi.org\/10.5114\/reum.2018.80718","journal-title":"Rheumatology"},{"key":"2149_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/eb-2018-102911","volume":"21","author":"O Efthimiou","year":"2018","unstructured":"Efthimiou O (2018) Practical guide to the meta-analysis of rare events. Evid Based Ment Health 21:72\u201376. https:\/\/doi.org\/10.1136\/eb-2018-102911","journal-title":"Evid Based Ment Health"},{"key":"2149_CR12","unstructured":"Feldman SR, Goffe B, Rice G et al (2016) The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits 9:504\u2013513"},{"key":"2149_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","volume":"92","author":"LK Ferris","year":"2025","unstructured":"Ferris LK, Bagel J, Huang Y-H et al (2025) FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 92:495\u2013502. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.076","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","volume":"91","author":"K Gebauer","year":"2024","unstructured":"Gebauer K, Spelman L, Yamauchi PS et al (2024) Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: a multicenter, randomized, double-blind, placebo-controlled, phase 3b study. J Am Acad Dermatol 91:91\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.025","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ddg.14585","volume":"19","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Augustin M, Baraliakos X et al (2021) TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. JDDG Journal der deutschen Dermatologischen Gesellschaft 19:1409\u20131420. https:\/\/doi.org\/10.1111\/ddg.14585","journal-title":"JDDG Journal der deutschen Dermatologischen Gesellschaft"},{"key":"2149_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"LS Gold","year":"2025","unstructured":"Gold LS, Armstrong AW, Bissonnette R et al (2025) Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet 406:1363\u20131374. https:\/\/doi.org\/10.1016\/S0140-6736(25)01576-4","journal-title":"Lancet"},{"key":"2149_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500155","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Lain E, Bissonnette R et al (2025) Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2500155","journal-title":"NEJM Evid"},{"issue":"1","key":"2149_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bjd.16008","volume":"178","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Blauvelt A, Foley P et al (2018a) Efficacy of guselkumab in subpopulations of patients with moderate\u2010to\u2010severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 178(1):132\u2013139. https:\/\/doi.org\/10.1111\/bjd.16008","journal-title":"Br J Dermatol"},{"key":"2149_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M et al (2018b) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392:650\u2013661. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6","journal-title":"Lancet"},{"key":"2149_CR20","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with R: a hands-on guide, 1st edn. Chapman and Hall\/CRC, Boca Raton","edition":"1"},{"key":"2149_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/1346-8138.16746","volume":"50","author":"M Komine","year":"2023","unstructured":"Komine M, Kim H, Yi J et al (2023) A discrete choice experiment on oral and injection treatment preferences among moderate\u2010to\u2010severe psoriasis patients in Japan. J Dermatol 50:766\u2013777. https:\/\/doi.org\/10.1111\/1346-8138.16746","journal-title":"J Dermatol"},{"key":"2149_CR22","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2149_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"2149_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB et al (2018) Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol 79:277-286.e10. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.037","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator\u2013controlled VOYAGE 2 trial. J Am Acad Dermatol 76:418\u2013431. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D et al (2019) Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 394:576\u2013586. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3","journal-title":"Lancet"},{"key":"2149_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L et al (2018) Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol 179:844\u2013852. https:\/\/doi.org\/10.1111\/bjd.16736","journal-title":"Br J Dermatol"},{"key":"2149_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126\u2013135. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.10.014","journal-title":"J Clin Epidemiol"},{"key":"2149_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub7","author":"E Sbidian","year":"2025","unstructured":"Sbidian E, Chaimani A, Guelimi R et al (2025) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub7","journal-title":"Cochrane Database Syst Rev"},{"key":"2149_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2339440","volume":"35","author":"SD Smith","year":"2024","unstructured":"Smith SD, Fifer S, Edwards M et al (2024) Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia. J Dermatolog Treat 35:2339440. https:\/\/doi.org\/10.1080\/09546634.2024.2339440","journal-title":"J Dermatolog Treat"},{"key":"2149_CR31","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J et al (2024) Efficacy of long\u2010term risankizumab treatment for moderate\u2010to\u2010severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial). J Eur Acad Dermatol Venereol 38:864\u2013872. https:\/\/doi.org\/10.1111\/jdv.19748","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2149_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, Van De Kerkhof P et al (2020) Recategorization of psoriasis severity: delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 82:117\u2013122. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H et al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 88:40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR34","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s13555-024-01270-5","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Ibba L, Cascio Ingurgio R et al (2024) A 3-year multicentric study on switching from Ustekinumab to Guselkumab in partial responders with psoriasis\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Ther 14:2987\u20132997. https:\/\/doi.org\/10.1007\/s13555-024-01270-5","journal-title":"Dermatol Ther"},{"key":"2149_CR35","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J (2017) Diagnosis and management of psoriasis. Can Fam Physician Med Fam Can 63:278\u2013285","journal-title":"Can Fam Physician Med Fam Can"},{"key":"2149_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.982238","volume":"13","author":"D-K Xiong","year":"2022","unstructured":"Xiong D-K, Shi X, Han M-M et al (2022) The regulatory mechanism and potential application of IL-23 in autoimmune diseases. Front Pharmacol 13:982238. https:\/\/doi.org\/10.3389\/fphar.2022.982238","journal-title":"Front Pharmacol"},{"key":"2149_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2021.02.012","volume":"135","author":"C Xu","year":"2021","unstructured":"Xu C, Furuya-Kanamori L, Zorzela L et al (2021) A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. J Clin Epidemiol 135:70\u201378. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.012","journal-title":"J Clin Epidemiol"},{"key":"2149_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Chen Y, Cui L et al (2022) Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 13:81. https:\/\/doi.org\/10.1038\/s41419-022-04523-3","journal-title":"Cell Death Dis"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02149-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:25:10Z","timestamp":1781699110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02149-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02149-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Cevallos-Cueva,\u00a0Chinenye Onejeme,\u00a0Laura Ghanem,\u00a0Lorena Oliveira Fonseca have no conflicts of interest. Stephen Tyring has done studies sponsored by the manufacturer of icotrokinra,\u00a0Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}